Hashimoto K, Sagawa M, Sato M, Nagamoto N, Usuda K, Ohta S, Kanma K, Imai T, Saito Y, Suda H
Gan No Rinsho. 1986 Oct;32(13):1752-6.
In order to improve the management of lung cancer at various stages, we analyzed results of treatment in 928 of 1024 patients who were registered at our Hospital Tumor Registry of 1952-1983 with a pathological diagnosis of TNM for carcinoma of the lung after pulmonary resection. The 5-year-survival rate was 43% in 928 patients excluded the cases who were lost follow-up or succumbed within post-operative 1 month. The 5-year-survival rate was 77% for the stage I, 54.7% for the stage II, 17% for the stage III and 4% for the stage IV. The 5-year-survival rate by therapeutic modality was as follows: 52% for the group with chemotherapy, 35% for the one without adjuvant therapies, 29% for the one with irradiation and 15% for the one with radiochemotherapy. Patients with adenocarcinoma who underwent curative surgery showed improvement of survival by postoperative chemotherapy. No increase in survival time was noticed in the irradiated group with N2.
为改善肺癌各阶段的管理，我们分析了1952年至1983年在我院肿瘤登记处登记的1024例经病理诊断为TNM的肺癌患者中928例肺切除术后的治疗结果。排除失访或术后1个月内死亡的病例后，928例患者的5年生存率为43%。I期患者的5年生存率为77%，II期为54.7%，III期为17%，IV期为4%。按治疗方式划分的5年生存率如下：化疗组为52%，未接受辅助治疗组为35%，放疗组为29%，放化疗组为15%。接受根治性手术的腺癌患者术后化疗可提高生存率。N2期放疗组患者的生存时间未增加。
